R.M Wolf1, N. Noor2, R. Izquierdo3, D. Jett3, A. Rewers4, S. Majidi4, N. Sheanon5, E. Breidbart6, C. Demeterco-Berggren7, J.M Lee8, M.K Kamboj9, O. Ebekozien10,2

1Johns Hopkins Medicine, Baltimore, USA, 2T1D Exchange, Boston, USA, 3SUNY Upstate Medical University, Albany, USA, 4Barbara Davis Center for Diabetes, Denver, USA, 5Cincinnati Children’s Hospital Medical Center, Cincinnati, USA, 6NYU Langone Pediatrics, New York City, USA, 7Rady Children’s Hospital, University of California, San Diego, San Diego, USA, 8Mott Children’s Hospital, Susan B. Meister Child Health Evaluation and Research Center, University of Michigan, Ann Arbor, USA, 9Nationwide Children’s Hospital, Columbus, USA, 10University of Mississippi Medical Center, Jackson, USA

Introduction: An increase in newly diagnosed type 1 diabetes (T1D) has been posited during the COVID-19 pandemic, but data have been conflicting.

Objectives: We aimed to determine trends in newly diagnosed T1D and severity of presentation at diagnosis for pediatric and adolescent patients during COVID-19 year (2020) as compared to the previous year (2019) in a multi-center data analysis across the United States.

Click here to read the full abstract